aviscera bioscience  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
Soluble TWEAK (sTWEAK) ELISA, Protein & Antibody

Alternative name:

  • Tumor necrosis factor ligand superfamily member 12
  • TNF-related weak inducer of apoptosis
  • Basement-membrane protein 40
  • APO3 ligand
  • Gene name TNFSF12/ APO3L/DR3LG
OBJECTIVE: Soluble TWEAK has recently been introduced as a potential mediator of cardiovascular disease. In this retrospective pilot study we thus sought to evaluate serum levels of soluble TWEAK (sTWEAK) patients with acute ST-elevation myocardial infarction (STEMI).
METHODS: Blood samples of 173 patients admitted to our hospital with acute STEMI (<24 h after symptom onset) were evaluated for their sTWEAK serum levels immediately at the time of admission and compared to those of patients with stable coronary artery disease (CAD) and healthy controls. Moreover, patients with STEMI were analyzed for their 30-day short-term outcome after acute STEMI. Adverse events were defined as the combined endpoint of cardiovascular death, resuscitation>24 h after reperfusion, cardiogenic shock or need for vasopressor therapy, repeated target vessel revascularization/myocardial infarction and stroke/TIA.
RESULTS: Patients with STEMI showed significantly higher levels of sTWEAK on admission compared to control patients or patients with chronic stable coronary artery disease (p<0.0001). Moreover, sTWEAK levels were higher in female patients. Additionally, sTWEAK levels were related to C-reactive protein levels and inversely correlated with the time between symptom onset and admission. Soluble TWEAK levels above the ROC-defined cutoff (>1286 pg/ml) significantly predicted an adverse short-term outcome in patients with STEMI after 30 days (p=0.0032). In this pilot study there was no significant relation between serum levels of sTWEAK and common risk factors like diabetes, hypertension, active smoking and age, white blood count or indices of myocardial function and damage like ejection fraction and infarct size in STEMI patients. Moreover, no significant relation was found between peak troponin T levels and sTWEAK on admission.
CONCLUSION: Our retrospective pilot study shows for the first time that sTWEAK is significantly elevated in patients with acute myocardial infarction compared to healthy controls and patients with stable coronary artery disease. Moreover, in our study sTWEAK levels on admission were associated with an adverse short-term outcome in STEMI patients. Further work is needed to precisely define the potential role of sTWEAK as a prognostic marker in myocardial infarction.
Chorianopoulos E, et al. Atherosclerosis. 2010 Jul;211(1):322-6. Epub 2010 Feb 21.
The multifunctional cytokine, TWEAK (TNF-like weak inducer of apoptosis), is a member of the TNFα superfamily. TWEAK is found in a broad range of cell types and has been linked to cell growth and survival, angiogenesis and other inflammatory processes. These functions and their importance in inflammatory diseases have made TWEAK an attractive pharmaceutical target, particularly for immunotherapy with monoclonal antibodies (mAbs). Immunotherapy targeting another TNFα family member, CD154, was associated with thrombosis in clinical trials. Subsequent studies identified platelets, which contain CD154, as a possible contributing factor to thrombosis in these trials. Since clinical trials with anti-TWEAK mAbs have already begun, we considered it important to determine whether platelets contain TWEAK. Using a variety of immunologic methods we found that, upon activation, human platelets expose TWEAK antigen and release it in soluble form (sTWEAK). By flow cytometry we determined that human platelets activated by TRAP (Thrombin Receptor Agonist Peptide) and other agonists expose TWEAK antigen (22% median positivity) and release TWEAK positive microparticles. The presence of TWEAK on platelets was confirmed by confocal microscopy. By ELISA, we found that sTWEAK is released by activated platelets. Finally, western blot analysis revealed TWEAK protein (34 kDa) in washed platelet lysates. The finding that human platelets contain TWEAK raises important questions about its possible functions in normal physiology, as well as in inflammatory diseases and their treatment.
Meyer T, et al. Platelets. 2010;21(7):571-4.
OBJECTIVE: To assess the prognostic value of the pro-apoptotic, but also cell growth-inducing molecule soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) in heart failure (HF).
METHODS: We assayed sTWEAK levels in 351 patients with advanced HF (non-ischemic: 130, ischemic: 221). During a median follow-up of 4.9 years, 195 patients (56%) died.
RESULTS: sTWEAK concentrations were associated with extended survival in patients with non-ischemic (P=0.022), but not with ischemic HF (P=0.82). The inverse association in non-ischemic HF remained significant in a multivariable Cox regression model (P=0.025) with a hazard ratio of 0.40 (95% confidence interval: 0.21-0.77) comparing the third to the first tertile (P=0.007).
CONCLUSION: Low sTWEAK levels independently predict mortality in advanced non-ischemic HF. sTWEAK-induced proliferation of cardiomyocytes may explain its impact on suvival. The different prognostic value of sTWEAK in ischemic and non-ischemic HF may point towards distinct pathogenic pathways determining the course of disease.
Richter B, et al. Atherosclerosis. 2010 Aug 19. [Epub ahead of print]
 
human tweak
 
mouse tweak
human soluble tweak elisa kit sk00577-06
   
Human sTWEAK ELISA
Code No.: SK00577-06
Size: 96 T
Price: $390.00 USD
Standard Range:62-4000 pg/ml
Sensitivity:15 pg/ml
Sample Type: EDTA plasma
Sample requres: 100uL per well
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
   
Mouse sTWEAK ELISA
Code No.: SK00577-03
Size: 96 T
Price: $460.00 USD
Standard Range:15.6-1000 pg/ml
Sensitivity:7.8 pg/ml
Sample Type: EDTA plasma
Sample requres: 100uL per well
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
Human Soluble TWEAK/TNFSF12
Code No.: 00577-02-10
Size: 10 ug
Price: $120.00 USD
Sequence: 98R-249H
Purity:>95%
Expression: CHO derived
Activity: <1 ng/ml
Endotoxin: <0.2 EU/up protein
  Human Soluble TWEAK/TNFSF12 Fc tag
Code No.: 00577-01-05
Size: 5 ug
Price: $130.00 USD
Protein ID: NP_003800.1
Gene ID: NM_003809.2
Sequence: Ser94-His249
Purity:>72%+25%
MW: 34 and 47 KDa
Expression: HEK293 cells derived
Activity: <2-8 ng/ml
Endotoxin: <1.0 EU/up protein
  Rat Soluble TWEAK/TNFSF12 Fc tag
Code No.: 00577-07-05
Size: 5 ug
Price: $130.00 USD
Protein ID: NP_001001513.2
Gene ID: NM_001001513.2
Sequence: Arg105-His249
Purity:>90%
MW:47 KDa
Expression: HEK293 cells derived
Activity: <5-20 ng/ml
Endotoxin: <1.0 EU/up protein
  Mouse Soluble TWEAK/TNFSF12 Fc tag
Code No.: 00577-04-05
Size: 5 ug
Price: $130.00 USD
Protein ID: NP_035744.1
Gene ID: NM_011614.3.
Sequence: Arg105-His249
Purity:>84%
MW:45 KDa
Expression: HEK293 cells derived
Endotoxin: <1.0 EU/up protein
  Human Soluble TWEAKR/TNFRSF12A Fc tag
Code No.: 00577-11-10
Size: 10 ug
Price: $160.00 USD
Protein ID:NP_057723.1
Gene ID: NM_016639.2.
Sequence: ECD plus Human IgG Fc
Purity:>95%
MW:37 KDa
Activity: <70 ~150 ng/ml
Expression: HEK293 cells derived
Endotoxin: <1.0 EU/up protein

 

 

Name
Code No.
Size
Price ($)
Soluble TWEAK (Human) ELISA Kit
96 T
390.00
Soluble TWEAK (Mouse) ELISA Kit
96 T
460.00
Soluble TWEAK (Human) Recombinant (CHO derived)
00577-02-10
10 ug
180.00
Soluble TWEAK (Human) Recombinant (CHO derived)
00577-02-20
20 ug
360.00
Soluble TWEAK (Human) Recombinant (CHO derived)
00577-02-1000
1 mg
Inquire
Soluble TWEAK (Human) Fc Tag (HEK293 derived)
00577-01-5
5 ug
130.00
Soluble TWEAK (Human) Fc Tag (HEK293 derived)
00577-01-20
20 ug
360.00
Soluble TWEAK (Mouse) Fc Tag (HEK293 derived)
00577-04-5
5 ug
130.00
Soluble TWEAK (Mouse) Fc Tag (HEK293 derived)
00577-04-20
20 ug
360.00
Soluble TWEAK (Rat) Fc Tag (HEK293 derived)
00577-07-5
5 ug
130.00
Soluble TWEAK (Rat) Fc Tag (HEK293 derived)
00577-07-20
20 ug
360.00
Soluble TWEAKR (Human) Fc Tag (HEK293 derived)
00577-11-5
5 ug
120.00
Soluble TWEAKR (Human) Fc Tag (HEK293 derived)
00577-11-10
10 ug
160.00